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Sjögren’s syndrome (SS) and autoimmune thyroid diseases (AITD) may frequently coexist 
in clinical practice, resulting in a complex overlapping disorder that represents a partic-
ular example of the expression of heterogeneity in patients with autoimmune disorders. 
Objective of this review was to describe the prevalence of the SS–AITD association in 
the most recent literature, exploring in particular to what extent the presence of AITD 
might influence the clinical expression of SS and vice versa. Moreover, we summarized 
some of the proposed genetic, biologic, and molecular mechanisms implied in the 
pathogenesis of AITD–SS association. Finally, we explored risk factors for lymphoma 
development in both AITD and SS. We performed a Medline search of English language 
articles published in the PubMed database in order to provide a critical overview of the 
recent literature on pathogenesis and clinical features of AITD–SS overlapping disease. 
All the articles were critically analyzed to select the most relevant contributions.
Keywords: Sjögren’s syndrome, autoimmune thyroid diseases, non-Hodgkin’s lymphoma, comorbidities, 
pathogenesis
inTRODUCTiOn
Sjögren’s syndrome (SS) is a complex and heterogeneous autoimmune disease that frequently co-
occurs with both organ-specific and non-organ specific, systemic rheumatic diseases (i.e., rheuma-
toid arthritis, systemic lupus erythematosus, and systemic sclerosis) offering a unique opportunity 
to investigate pathogenesis, long-term-evolution, and outcome of different autoimmune phenotypes 
and subsets (1–5).
The association of SS and autoimmune thyroid diseases (AITD) has been largely documented, 
suggesting that AITD could be overrepresented in patient with SS with respect to general population 
and vice versa (6). Interestingly, Rojas-Villarraga et al. (7) analyzing prevalence of multiple autoim-
mune syndromes in 1,083 patients belonging to four autoimmune disease cohorts described AITD 
and SS as the most frequent coexisting autoimmune disorders in single patients. Overall, then, it 
has been hypothesized that common genetic, immunologic, and biologic factors may be implied in 
SS and AITD, leading to the coexistence of these two conditions (8). Moreover, both SS and AITD 
may lead to the development of non-Hodgkin’s lymphoma (NHL) highlighting the relationship 
between similar autoimmunity pathways and lymphoproliferation (9, 10). Although the majority of 
data support an increased prevalence of AITD in SS patients, some authors have suggested that this 
observation might be related to the age and sex distribution of SS and AITD rather than representing 
a true association. However, literature data are difficult to compare due to the fact that different SS 
classification criteria and AITD definitions have been utilized over the years, making it difficult to 
define the exact prevalence of SS–AITD association (11, 12).
TAble 1 | Prevalence of AITD in Sjögren’s syndrome.
Reference Year no. PTs Prevalence (%)
HT GD Anti-TPO Anti-Tg
Karsh et al. (30) 1980 24 nd nd 41.6 20.8
Kelly et al. (31) 1991 100 14 nd 40 nd
Hansen et al. (32) 1991 28 18 nd 36 nd
Bouanani et al. (33) 1991 26 11.5 nd nd 100
Foster et al. (34) 1993 42 nd nd 36 36
Perez et al. (35) 1995 33 24 6 45 18
Punzi et al. (36) 1996 121 7 nd 17.6 13.4
Davidson et al. (37) 1999 74 nd nd 22.8 nd
Ramos Casals et al. (38) 2000 160 20 1.25 15.6 12.5
D’Arbonneau et al. (39) 2003 137 14.6 0.7 10.9 2.9
Tunc et al. (40) 2004 53 4 nd 9 9
Lazarus and Isenberg (41) 2005 114 16 1.8 nd nd
Biro et al. (19) 2006 400 7 3 nd nd
Mavragani et al. (11) 2009 54 nd nd 20.4 18.5
Zeher et al. (42) 2009 479 6.3 3.8 nd nd
Caramaschi et al. (43) 2013 100 27 nd nd nd
nd, not done; HT, Hashimoto’s thyroiditis; GD, Graves’ disease; Anti-TPO, anti 
thyroperoxidase antibodies; anti-Tg, antithyroglobulin antibodies, PTs, patients.
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In this review, we aimed at describing the frequency of the 
SS–AITD association in the most recent literature, exploring, in 
particular, to what extent the presence of AITD may influence 
the clinical expression of SS. Moreover, we will summarize some 
of the proposed pathogenetic mechanisms for the coincidence 
of SS and AITD and the common biologic factors involved into 
lymphoproliferative complications.
Prevalence of SS in AiTD: A Clinical 
Spectrum Ranging From isolated Sicca 
Symptoms to Full-blown SS
Autoimmune thyroid diseases, namely, Hashimoto’s thyroiditis 
(HT) and Graves’ disease (GD), are organ-specific autoimmune 
disorders, essentially resulting from a T cell-mediated immune 
attack of the thyroid resulting into lymphocytic infiltration of 
the thyroid parenchyma (13). The association between AITD and 
other organ specific (polyglandular autoimmune syndromes), 
or systemic rheumatic disorders has been widely described. SS 
is perhaps the most frequently rheumatic autoimmune disease 
associated with AITD, and particularly with HT. Several authors 
have reported that a full-blown SS could be 10 times higher in 
AITD than in the general population (14). In fact, the prevalence 
of SS in AITD has been assessed by several heterogeneous studies 
over the time and apparently varies from 3% up to 32% (15–17).
In 1992, Warfvinge et al. (18), analyzing different degrees of 
morphologic and functional salivary gland changes in AITD, 
found that 11 patients out of 19 presented xerostomia, a compro-
mised unstimulated salivary flow and alterations of their lower 
lip biopsy, and/or parotid scintigraphy. Six of them presented a 
true SS. Similarly, Tektonidou (16) in a cohort of 58 patients with 
antinuclear antibodies positive AITD found that 9% fulfilled the 
criteria for SS. These data on small cohorts were confirmed also 
in large population studies over the years. For example, Biro et al. 
(19) evaluating the prevalence of SS in 426 patients with HT or 
GD found that SS had a prevalence of 17% in HT and of 5% in 
GD. Similarly, Lu et al. (20) observed that the risk of SS in patients 
with thyroiditis was 3.6 times higher than in individuals without 
thyroiditis.
The spectrum of sicca symptoms in patients with AITD that 
do not fulfill the criteria for SS is even more common. More 
specifically, Coll et al. (21) in a cohort of 176 patients with AITD 
found that 19 of 52 (37%) patients presented isolated xerostomia 
and 39/170 (23%) isolated keratoconjunctivitis sicca. Other 
authors described an isolated positivity for antinuclear antibod-
ies in 25–55% of patients with AITD. The real implication of 
antinuclear antibodies positivity in AITD patients has to be clari-
fied, but it is generally believed that they may reflect polyclonal 
activation and antibody production that over time may trigger 
the development of concomitant systemic autoimmune diseases 
including SS (22). In clinical settings, patients with AITD and a 
positivity for antinuclear antibodies should then be monitored 
more closely for the development of SS during the follow-up.
Overall, the available literature suggests that both a full blown 
SS and “incomplete” subsets of SS may be quite common among 
patients with AITD. Among these incomplete forms, an impor-
tant differential diagnosis is represented by patients with sicca 
symptoms, affected by fibromyalgia. Patients with fibromyalgia 
often present dry eyes and dry mouth and noteworthy, they 
may present AITD or a positivity for thyroid auto antibodies as 
well. In the study by Mavragani et al. (23), fibromyalgia patients 
with sicca symptoms presented thyroid auto antibodies with 
a prevalence of 60%. Besides fibromyalgia, a number of other 
systemic disorders associated with AITD also involves salivary 
glands and should be considered as well in the differential diag-
nosis. Infectious diseases like hepatitis C virus and Ebstein B 
virus infections are among the major mimickers of SS in AITD 
patients, especially due to viral lymphotropism and epithelial 
tropism (24, 25). Immune disorders including sarcoidosis and 
IgG4 disease may be considered as well. The latter represents a 
novel entity characterized by high serum IgG4 and IgG4 plasma 
cell-mediated fibro-inflammatory lesions that may involve not 
only thyroid but also lung, pancreas, kidney, and salivary and 
lacrymal glands (26). More specifically, IgG4 has been linked 
to four types of thyroid diseases including: Riedel’s thyroiditis, 
fibrosing variant of Hashimoto’s thyroiditis, IgG4-related 
Hashimoto’s thyroiditis, and GD with elevated IgG4 levels (27). 
The pathogenetic role of IgG4 in these IgG4-related thyroid dis-
eases, however, still remains poorly understood. Those patients 
may often present with an SS-like subacute diffuse enlargement 
of lacrymal and salivary glands and sicca symptoms. A minor 
salivary gland biopsy is often necessary to distinguish IgG4 
disease from SS (28, 29).
Prevalence of AiTD in SS: A Specific 
Subset of the Disease?
Several uncontrolled studies have described the presence of AITD 
in SS with frequencies ranging between 10 and 30% (8). Table 1 
summarizes the most important studies reporting frequency of 
AITD in SS. The differences observed among these studies might 
be linked to the different ethnic origin of the patients or to the 
diagnostic criteria adopted for both SS and HT classification.
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As far as the clinical manifestation of AITD in SS, three studies 
are particularly relevant. In the study by Lazarus and Isenberg 
(41), 16% of the SS patients developed AITD. The most common 
clinical manifestation of AITD in SS was hypothyroidism, even 
though subclinical AITD was probably more common. In the vast 
majority of the cases, hypothyroidism had been diagnosed before 
the diagnosis of SS: similarly, Jara et  al. (6) in a cohort of 160 
primary SS patients found evidence of thyroid disease in 36% of 
patients: 20% were diagnosed as AITD and 16% were diagnosed 
as non-AITD. The clinical pattern in more than half of primary 
SS patients was subclinical hypothyroidism. Finally, in the study 
by Zeher et  al. (42) 479 patients with pSS were investigated 
with regard to several types of thyroid disease. Overall, thyroid 
dysfunction was found in 95 patients (21.25%). Apparently, the 
diagnosis of HT and GD may be present either before or after 
the onset of SS but, differently from the study by Lazarus and 
Isenberg (41), both HT and GD were more likely to follow SS. 
The authors found that in 50% of the cases SS preceded HT by 
5.5 years. Interestingly, D’Arbonneau et al. (39) showed that the 
presence of thyroid-related autoantibodies represented a risk 
factor for development of AITD during follow-up.
Finally, regarding the clinical impact of AITD on the clinical 
course, literature data are quite heterogeneous especially due to 
different control groups that have been included (i.e., SS–AITD 
versus SS without AITD; SS–AITD versus AITD) and to the 
classification criteria adopted to define SS. However, Caramaschi 
et al. (43) demonstrated that the association of AITD in patients 
suffering from SS defined a subset of patients with milder disease 
and normal complement 4 levels. More specifically, patients with 
AITD–SS had less evidence of cryoglobulins, palpable purpura, 
peripheral neuropathy, and lymphoma. This observation has been 
confirmed by several additional studies. However, it is nowadays 
widely accepted that AITD–SS patients are at a greater risk of 
developing additional autoimmune diseases such as autoimmune 
liver diseases, inflammatory bowel diseases, and systemic lupus 
erythematosus and should be closely monitored over the follow-
up due to their tendency to present widespread disorders of their 
immune systems.
SS and AiTD: Common Pathogenetic 
Mechanisms From epithelitis to  
non-Hodgkin lymphoma
A large amount of data have highlighted that AITD and SS can be 
considered as pathogenetically correlated. First of all, these two 
disorders are characterized by similar histological features with a 
tissue infiltrate that consists primarily of CD4+ T lymphocytes 
and the possible formation of germinal center-like structures 
unrevealing B cell activation (8). Second, from a genetic point of 
view, the two conditions present a similar background with thy-
roid and epithelial cells expressing the same HLA molecules class 
II: HLA-B8 and HLA-DR3 (8). In particular, HLA-B8 and -DR3 
haplotypes have been reported with a higher frequency in both 
primary SS and AITD whereas cytotoxic T lymphocytic antigen 
4 gene polymorphisms have been reported more frequently in 
patients with AITD and other autoimmune diseases including 
rheumatoid arthritis (15).
A third point to take into account is the existence of animal 
models that spontaneously develop both SS and AITD. Thyroiditis 
and SS in NOD.H-2h4 mice are chronic autoimmune diseases 
that develop relatively early in life and persist for the life of the 
animal making them an excellent model to test therapeutic pro-
tocols over a long period of time (44).
Another point reinforcing the pathogenetical link between 
AITD and SS is represented by the crucial role of the epithelial 
cells in orchestrating the tissue inflammation and the involvement 
of several regulatory chemokines, such as the IFN-γ-inducible 
protein 10 (IP-10/CXCL10) in initiating and perpetuating the 
autoimmune process. CXCL10 exerts its function through bind-
ing to chemokine (C-X-C motif) receptor 3 (CXCR3), and its 
production is stimulated by IFN-γ and TNF-α, whose production 
in turn is provided by T helper 1 cells (Th1) (45).
In AITD, it has been postulated that CXCL10 could be a 
marker of a stronger and more aggressive inflammatory response, 
subsequently leading to thyroid destruction and hypothyroid-
ism (45). Similarly, epithelial cells from SS patients apparently 
produce CXCL9 and CXCL10 as well, while most of the CD3+ 
lymphocytes in periductal foci express CXCR3, thus contributing 
to salivary gland damage (46).
Another cytokine that exerts a fundamental role in the 
pathogenesis of both AITD and SS is B-cell activating factor that 
seems to be especially important for the survival of autoreactive 
B cells (47). Serum B-cell activating factor concentrations were 
described as significantly higher in GD and correlated with serum 
antithyroglobulin antibodies (48). B-cell activating factor has 
been also correlated to disease activity and severity in SS exerting 
a key role in lymphoproliferative complications (49–52).
Not surprisingly, both AITD and SS may evolve into B-cell 
NHLs of salivary glands and thyroid, with a prevalence of 0.5 and 
5%, respectively (9). Intriguingly cases of patients with AITD, SS, 
and NHL have been described even if the vast majority of the 
studies seem to support the evidence that AITD–SS patients have 
a lower risk of developing NHL compared to SS patients without 
AITD (53–56). It remains a matter of debate whether the presence 
of SS in AITD patients may increase the risk of thyroid lymphoma 
in AITD patients.
The striking association between SS, AITD, and NHL has 
provided valuable insights into the relationship between autoim-
munity and lymphoproliferation. In this multistep process, key 
players are represented by chronic inflammation and sustained 
antigenic stimulation that are apparently able to promote B-cell 
activation and proliferation. Immune deregulation, moreover, 
sometimes promotes B cell proliferation mediated by infectious 
agents (i.e., suppression/dysregulation of T-cells leading to EBV-
driven B-cell proliferation) (57, 58). Ultimately, SS and AITD 
seem to be characterized by a wide spectrum of genetic and 
molecular abnormalities that culminate in uncontrolled B-cell 
activation, proliferation, and neoplastic transformation.
Conclusion
The coexistence of SS and AITD occurs frequently in clinical 
practice probably due to common pathogenetic mechanisms 
shared by these two conditions. From a practical point of view, 
it is important to screen patients with SS for AITD and vice versa 
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because the presence of the two disorders may influence patients’ 
clinical presentation and long-term outcome. It is widely accepted 
that AITD–SS patients may have a milder phenotype of SS with 
a lower risk for lymphoma development. However, it remains 
unclear whether a concomitant diagnosis of SS may increase or 
not the risk for thyroid lymphoproliferative complications in 
AITD patients. Intriguingly, AITD–SS patients over the follow up 
frequently present additional autoimmune diseases and should 
be closely monitored especially for liver autoimmunity. Further 
studies are warranted to explore genetic, biologic, and molecular 
factors underlying the SS–AITD association in order to provide 
further insights for the comprehension of this complex and varied 
subset of autoimmunity.
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